Simon Nazarian was named executive vice president and chief digital and technology officer at City of Hope. He will join the institution on Sept. 9.
Omer F. Awan was named vice president and chief information officer at Fred Hutchinson Cancer Center, effective Sept. 25.
Jonathan H. Sherman has been appointed chief of neurosurgical oncology at Rutgers Cancer Institute.
Abhisek Swaika was named medical director of the Northwell Health Cancer Institute at Rego Park and chief of hematology/oncology at Long Island Jewish Forest Hills Hospital.
The UCSF Prostate Cancer Program received the NCI’s Specialized Programs of Research Excellence, or SPORE, grant for prostate cancer.
Researchers at Indiana University School of Medicine, Mayo Clinic, Washington University in St. Louis, the University of Pennsylvania, Columbia University, and Intel received a five-year, $3.7 million NCI grant for a multi-site study developing a privacy-preserving artificial intelligence approach—called federated learning—which aims to improve breast cancer risk prediction and reduce health inequities in cancer prevention care.
Michele CarboneHaining YangMichele Carbone and Haining Yang, researchers at the University of Hawai’i Cancer Center, received a $2.5 million NCI grant to advance mesothelioma research by improving diagnosis and treatment for the disease.
CureSearch for Children’s Cancer will award $2 million in funding to support a phase I clinical trial in 24 children and young adults with recurrent brain tumors.
The FY24 Defense Appropriations Act provides funding for the Glioblastoma Research Program to support high impact research to reduce the burden of glioblastoma on service members and their families, veterans, and the American public.
Incyte announced positive topline results from the phase III inMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, or placebo in combination with lenalidomide (Revlimid) and rituximab (Rituxan) compared to lenalidomide and rituximab alone in patients with relapsed or refractory follicular lymphoma.
